Caryn Lerman/LinkedIn
Jun 27, 2025, 07:09
Caryn Lerman: New Compound Targets Circadian Clock Machinery in Cells to Fight Glioblastoma
Caryn Lerman, Director of Norris Comprehensive Cancer Center at Keck Medicine of USC, shared a post on LinkedIn:
“Glioblastoma is the most common cancerous brain tumor in adults—and one of the most difficult to treat. Most patients receive a combination of surgery, radiation and chemotherapy, but tumors typically return and resist further treatment.
Published in the journal Neuro-Oncology, USC Norris member Dr. Steve Kay and his team demonstrated that a new drug compound, SHP1705, targets circadian clock proteins hijacked by glioblastoma stem cells, impairing the cancer cells’ ability to survive and grow, with minimal impact on healthy cells.
When they treated glioblastoma stem cells with other drug compounds developed to target clock proteins, none worked as well as SHP1705. SHP1705 is also the first clock-targeting compound to complete a phase 1 clinical trial, where they tested SHP1705’s ability to neutralize glioblastoma stem cells, finding it to be highly effective, safe, and well-tolerated in humans.
Learn More.”
Video attached to the post.
More posts featuring Caryn Lerman on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 27, 2025, 07:03
Jun 27, 2025, 06:53
Jun 27, 2025, 06:44